<DOC>
	<DOC>NCT00992563</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability, and effects of investigational drug AL-39324 for the treatment of wet AMD.</brief_summary>
	<brief_title>WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment Examination</brief_title>
	<detailed_description>Following a single administration, patients will be followed for 6 months postinjection.</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Willing to give written informed consent, make the required study visits and follow instructions; The study eye: must have a primary diagnosis of choroidal neovascularization (CNV) secondary to AMD; lesion must be no larger than 30 mm2; must have edema measuring greater than 340 Î¼m; must have a visual score between 73 and 34 letters, inclusive; must be able to have clear picture taken of the back of the eye; Other protocoldefined inclusion criteria may apply. The study eye must not have been treated for exudative AMD previously; The study eye must not have any other ocular disease, condition, infection, or recent surgery that would interfere with vision or examination of the back of the eye; The study eye must not have uncontrolled glaucoma; The study eye must not be missing a lens; Must not be taking any medication that is toxic to the lens; Must not be taking oral or ocular corticosteroids; Must not have an unstable or progressive condition that would interfere with study visits; Must not have allergies to any component of the test article or sensitivity to fluorescein dye; If female, must not be pregnant or nursing and must agree to adequate birth control; Must not be participating in another drug or device study within 30 days of screening for this study; Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>wet age-related macular degeneration, exudative</keyword>
</DOC>